Deals and Financings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Becton Dickinson has reached a definitive agreement to acquire CR Bard for $24bn. BD says Bard's product portfolio gives it a strong presence in fast-growing clinical areas and more reach outside the US while Bard expects to reach more customers by building on BD's leadership in medication management and infection prevention.
Latest From Deals
On this week's Medtech Insight podcast we highlight two big M&A deals: Abbott & Alere, and Medtronic & Cardinal Health.
Cellnovo has signed a commercial license agreement with digital health firm TypeZero to integrate its artificial pancreas software technology into Cellnovo’s digitally connected insulin patch pump. The integrated product is expected to launch in 2018.
Underlining its focus on 3D-printing and the potential this technology can bring, DePuy Synthes has acquired the 3D-printed scaffold platform of Tissue Regeneration Systems, enabling the orthopedics leader to develop patient-specific trauma products in-house.
Medtronic is selling certain lower-margin, lower growth assets within its Patient Monitoring and Recovery division to Cardinal Health in a $6.1bn deal. While the deal may benefit Medtronic's debt situation, the same cannot be said for the buyer.
From crowdfunding to taking on its distributor partner as investor, the varied fundraising routes that HiberGene traveled down for its series B round has enabled the Irish rapid molecular diagnostic test developer to raise €6.7m.
Swiss firm LifeWatch has been offered a sweeter acquisition deal from BioTelemetry at a proposed CHF260m. The company was recently subject to a proposed takeover by investment firm Aevis Victoria SA.
M&A deal activity waned in March, with a total of 9 deals completed in the month, down from 12 in February and 17 in March 2016. This third month brought the total number of deals for Q1 2017 to 33, a significant year-on-year decline compared to 51 in the first quarter of 2016.
German pharma company Grünenthal is expanding its medical device portfolio with the acquisition of surgical adhesives specialist Adhesys Medical. The deal is expected to help Grünenthal achieve its five-year goal of hitting €2bn in sales by 2022.
It had been a slow start to the year but one unusually large financing round from cancer diagnostics company Grail means the first quarter of 2017 has now outpaced the performance from any in the previous four years.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.